Results 171 to 180 of about 10,236,148 (357)
D2 receptor ablation in indirect‐pathway striatal neurons reduces or abolishes dyskinetic and dystonic behaviors induced by L‐DOPA or D2 receptor agonists, respectively. Contralateral turning is reduced, while forward locomotion is increased. These effects are associated with modulation of neuronal activity in dorsal striatum and external globus ...
Laura Andreoli +5 more
wiley +1 more source
Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease. [PDF]
Gail Walkinshaw, Catherine Waters
openalex +1 more source
The aim of this study was to assess changes in L-3, 4- dihydroxyphenylalanine (L-DOPA) biotransformation in response to two-pulse infusion of L-DOPA into the striatum of freely-moving young (3-4 month) and old (21-26 month) male Wistar rats. In addition,
SHUI, HAO-AI;PENG, YING-I;WU, RUEY-MEEI;TSAI, YUAN-FEEN +1 more
core
Levodopa Efficacy and GLP‐1 Receptor Agonists
Movement Disorders Clinical Practice, EarlyView.
Catherine Martinez +3 more
wiley +1 more source
Abstract Deep brain stimulation (DBS) effectively treats motor symptoms in movement disorders but often compromises speech through incompletely defined mechanisms. We conducted a PROSPERO‐registered systematic review and meta‐analysis of publications through August 2024 (CRD42024527738).
Elina Tripoliti +15 more
wiley +1 more source
The Catalytic Mechanism of Decarboxylation of L‐DOPA to Dopamine by Papaver somniferum Aromatic Amino Acid Decarboxylase – A Computational Study [PDF]
João P. M. Sousa +2 more
openalex +1 more source
H2S-releasing L-DOPA derivatives for Parkinson disease
L-DOPA is the most widely used therapy for Parkinson disease but it does not arrest progression of the disorder. Factors that contribute to the continuing neuronal loss are oxidative stress, including oxidation of L-DOPA, and neurotoxins generated by ...
M. LEE +5 more
core
Phenotypic Clues in Infantile‐Onset Parkinsonism‐Dystonia‐2: A Treatable Neurotransmitter Disorder
Movement Disorders Clinical Practice, EarlyView.
Sangeetha Yoganathan +10 more
wiley +1 more source
ABSTRACT Background Dopa‐responsive dystonia is caused by pathogenic variants in the GCH1 gene. Although its clinical features and reduced penetrance are known, in vivo metabolic and structural alterations in symptomatic (sMC) and asymptomatic mutation carriers (aMC) remain poorly understood.
Jannik Prasuhn +12 more
wiley +1 more source
Enhanced Cell Adhesion Properties of a Collagen‐Mimicking Peptide Through Site‐Specific L‐DOPA Incorporation [PDF]
Mor Pasi +6 more
openalex +1 more source

